Core Viewpoint - A class action lawsuit has been filed against Ready Capital Corporation for alleged violations of securities laws, specifically related to misleading statements about its financial health and non-performing loans in its commercial real estate portfolio [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Ready Capital's securities between November 7, 2024, and March 2, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Company Financial Issues - Ready Capital reportedly made false and misleading statements regarding its financial condition, particularly concerning its commercial real estate loans [4]. - The company attempted to stabilize its commercial real estate portfolio by fully reserving non-performing loans but failed to accurately reflect expected credit losses and valuation allowances in its financial results [4]. - As a result of these misleading statements, investors suffered damages when the true financial situation of Ready Capital was revealed [4].

Financial Data and Key Metrics Changes - In 2024, Logan Ridge achieved the highest total investment income and net investment income in its history, amounting to $20.9 million and $4.2 million respectively, with a net investment income per share of $1.56 [6] - For Q4 2024, the company generated $5.4 million in investment income, a $0.3 million increase from Q3 2024 [18] - Net investment income for Q4 was $1.5 million or $0.56 per share, an increase of $0.5 million or $0.19 per share from the previous quarter [20] - The net asset value as of December 31, 2024, was $85.1 million, a decrease of $1.2 million or 1.4% from the prior quarter [20] Business Line Data and Key Metrics Changes - The fair value of Logan's portfolio as of December 31, 2024, was approximately $172.3 million, with exposure to 59 portfolio companies, compared to $75.6 million with the same number of companies in the prior quarter [13] - The debt investment portfolio represented 83.3% of the total portfolio at fair value, with a weighted average annualized yield of approximately 10.7% [15] - The equity portfolio represented 13.4% and 13.8% of the portfolio on a cost and fair value basis respectively as of December 31, 2024 [16] Market Data and Key Metrics Changes - The company ended 2024 with no new non-accruals during Q4, maintaining stability in its investment portfolio [8] - As of December 31, 2024, four debt investments across three portfolio companies were on non-accrual status, with an aggregate amortized cost of $17.2 million and fair value of $7.9 million [16] Company Strategy and Development Direction - The successful sale of the largest equity position, Nth Degree, for $17.5 million was a significant catalyst for the merger with Portman Ridge, which is expected to provide greater scale and improved operating efficiencies [7][9] - The company aims to continue reducing equity exposure and reinvesting proceeds into yield-generating investments [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to deliver meaningful returns to stakeholders, supported by a healthy deployment pipeline and disciplined investment strategy [11] - The board approved a dividend of $0.36 per share for Q4 2024, remaining flat compared to the prior quarter, reflecting strong financial performance [11] Other Important Information - The company successfully amended and extended its revolving credit facility with KeyBanc, reducing financing costs and increasing financial flexibility [8] - As of December 31, 2024, the company had $15 million in cash and cash equivalents, along with $26.2 million of unused borrowing capacity available for new investments [21] Q&A Session Summary Question: Will the Logan portfolio be subsumed into Portman Ridge or will there be further reductions in equity exposure? - Management indicated that the merger will be a straightforward blending of portfolios, with a continued focus on reducing equity exposure [26][28] Question: Will there be significant overlaps in board members post-merger? - All Logan board members will overlap with Portman, with additional members from Portman joining the board [32] Question: Is there consideration for board member compensation to be purely in stock? - Management noted that there has been no discussion on this, and there may be regulatory restrictions preventing stock compensation for executives and board members [35][36]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Ready Capital Corporation regarding a class action lawsuit due to alleged misleading statements and undisclosed information related to non-performing loans in its commercial real estate (CRE) portfolio [1]. Summary by Sections Allegations - The complaint alleges that during the class period from November 7, 2024, to March 2, 2025, Ready Capital Corporation made materially false and misleading statements [1]. - Key allegations include: 1. Significant non-performing loans in its CRE portfolio were unlikely to be collectible 2. Ready Capital intended to fully reserve these problem loans to stabilize its CRE portfolio 3. This situation was not accurately reflected in the company's expected credit loss or valuation allowances 4. Consequently, the company's financial results would be adversely affected 5. Positive statements made by the defendants regarding the company's business and prospects were materially misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by May 5, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Group 1 - Tevogen Bio, a clinical-stage specialty immunotherapy biotech company, is leveraging AI to enhance precision medicine and operational efficiencies [2][3][5] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to AI [5][6] - Tevogen Bio aims to make advanced therapies more accessible and affordable by combining proprietary datasets with generative AI models [3][5] Group 2 - The recent AI discussion panel featured industry leaders discussing the transformative impact of AI across finance, biotech, and legal sectors [2][4] - The event highlighted the importance of tailoring AI applications to address unique challenges within each industry [3][4] - Tevogen Bio's leadership emphasizes the need for disruptive business models to sustain medical innovation and ensure patient accessibility [5][6]

Core Viewpoint - The article highlights Medallion Financial (MFIN) as a strong value stock, supported by its favorable valuation metrics and Zacks Rank of 2 (Buy) [4][7]. Valuation Metrics - MFIN has a P/E ratio of 5.15, significantly lower than the industry average of 9.56, indicating potential undervaluation [4]. - The company’s P/B ratio stands at 0.47, compared to the industry average of 1.04, suggesting that MFIN is trading below its book value [5]. - MFIN's P/CF ratio is 3.75, which is attractive relative to the industry average of 8.61, further supporting the notion of undervaluation based on cash flow [6]. Historical Performance - Over the past year, MFIN's P/E has fluctuated between a high of 6.36 and a low of 3.85, with a median of 4.73 [4]. - The P/B ratio has ranged from a high of 0.55 to a low of 0.38, with a median of 0.45 [5]. - MFIN's P/CF ratio has seen a high of 4.42 and a low of 2.48, with a median of 3.31 over the past 52 weeks [6]. Investment Outlook - Given the strong earnings outlook and attractive valuation metrics, MFIN is positioned as a compelling value investment opportunity at this time [7].